Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q1CD
|
|||
| Former ID |
DCL000243
|
|||
| Drug Name |
Tanomastat
|
|||
| Synonyms |
Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lung cancer [ICD-11: 2C25.0] | Discontinued in Phase 3 | [1], [2] | |
| Osteoarthritis [ICD-11: FA00-FA05] | Discontinued in Phase 3 | [1], [2] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Discontinued in Phase 3 | [1], [2] | ||
| Pancreatic cancer [ICD-11: 2C10] | Discontinued in Phase 3 | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Bayer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H19ClO3S
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)SCC(CC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)Cl)C(=O)O
|
|||
| InChI |
1S/C23H19ClO3S/c24-20-12-10-17(11-13-20)16-6-8-18(9-7-16)22(25)14-19(23(26)27)15-28-21-4-2-1-3-5-21/h1-13,19H,14-15H2,(H,26,27)/t19-/m1/s1
|
|||
| InChIKey |
JXAGDPXECXQWBC-LJQANCHMSA-N
|
|||
| CAS Number |
CAS 179545-77-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6468). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010243) | |||
| REF 3 | Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:44-6. | |||
| REF 4 | Conflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth J Natl Cancer Inst. 2006 Jun 7;98(11):726-7. | |||
| REF 5 | A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surg... Gynecol Oncol. 2006 Aug;102(2):300-8. | |||
| REF 6 | Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.